10 Essential Facts About CSL Plasma 161: The Ultimate Guide

Published 25 August 2026

The CSL Plasma 161 refers to a specialized plasma collection facility operated by CSL Limited, a global leader in plasma-derived therapies. Located in the United States, this facility is one of several advanced centers where donors contribute plasma, which is then processed into life-saving treatments like immunoglobulins and clotting factors. For instance, the plasma collected at CSL Plasma 161 is used to produce CSL Behring’s Immunoglobulin G (IgG) products, essential for patients with primary immunodeficiencies or chronic inflammatory conditions.

CSL Plasma 161 plays a critical role in the biopharmaceutical industry by ensuring a steady supply of high-quality plasma for therapeutic use. Plasma-derived medicines address unmet medical needs, from rare diseases to autoimmune disorders, making facilities like this indispensable. Historically, plasma collection has evolved from small-scale operations to large-scale, regulated processes, with CSL’s centers setting benchmarks for safety and efficiency.

This guide explores the inner workings of CSL Plasma 161, its impact on medical treatments, and practical insights for donors and patients. Topics include the collection process, safety protocols, career opportunities, and how plasma donations translate into real-world therapies.

1. How Plasma Collection Works at CSL Plasma 161

CSL Plasma 161 operates under stringent regulatory guidelines, including those from the FDA and AABB (formerly the American Association of Blood Banks). The process begins with donor screening, where medical professionals assess eligibility based on health history, lab tests, and physical exams. Once approved, plasma is collected via plasmapheresis, a method that separates plasma from blood cells, which are then returned to the donor.

For example, a donor might spend about 90 minutes at the facility, with the actual plasma collection taking around 60–90 minutes. The plasma is then transported to CSL’s manufacturing plants, where it undergoes purification and formulation into therapies. This closed-system process minimizes contamination risks and ensures product integrity.

The efficiency of CSL Plasma 161 lies in its automated equipment and trained staff, who monitor donors throughout the session. Donors can return every 28 days, allowing for frequent contributions that directly support therapeutic production.

2. Key Benefits of Donating Plasma at CSL

Donating plasma at CSL Plasma 161 offers tangible rewards, both financial and health-related. Here’s how it breaks down:

• Compensation: Donors receive payment per session, typically ranging from $50 to $100, depending on local rates and plasma volume. For example, a donor in Texas might earn $75 per donation, with bonuses for frequent contributions. This income can be particularly valuable for individuals in need of flexible cash flow.
• Health Monitoring: Regular plasma donations provide donors with free health screenings, including blood pressure, hemoglobin, and infectious disease tests. CSL’s facility in 161 prioritizes donor well-being, offering immediate feedback on results. This proactive approach can help donors catch early signs of conditions like anemia or diabetes.
• Therapeutic Impact: Each donation translates into treatments for patients. For instance, one plasma unit can produce enough Immunoglobulin (IgG) to treat multiple doses for someone with a rare immune disorder. Knowing this connection motivates donors to contribute consistently.
• Career Flexibility: Plasma donation is a part-time opportunity with no strict hourly commitment, making it ideal for students, retirees, or those seeking supplemental income. CSL’s centers often accommodate schedules, with sessions available early mornings, evenings, and weekends.
• Community Contribution: Donors become part of a network supporting medical research and patient care. CSL’s transparency about how plasma is used—such as in clotting factor concentrates for hemophilia patients—reinforces the direct impact of each donation.

3. Safety and Regulatory Standards at CSL Plasma 161

Safety is the cornerstone of CSL Plasma 161 operations, governed by FDA 21 CFR Part 640 and AABB standards. The facility employs single-use, disposable collection kits to prevent cross-contamination, and all equipment is sterilized between uses. Donors undergo rigorous screening, including a 12-month deferral period for travel to malaria-risk areas and lifetime deferrals for conditions like hepatitis or HIV.

For example, CSL’s Plasma Protein Therapeutics (PPT) division conducts additional testing on collected plasma, including nucleic acid testing (NAT) for viruses like HIV and hepatitis. This multi-layered approach ensures that only the highest-quality plasma enters the manufacturing pipeline. The facility’s compliance with Good Manufacturing Practices (GMP) further guarantees that therapies derived from CSL Plasma 161 meet global safety standards.

Transparency is another pillar of safety. CSL publishes annual reports detailing donation volumes, adverse event rates, and quality control measures. In 2022, the company reported a 0.01% adverse event rate during plasma collection, underscoring its commitment to donor and patient safety.

4. Plasma-Derived Therapies: From CSL Plasma 161 to Patients

The plasma collected at CSL Plasma 161 is a raw material for therapies that treat conditions ranging from hemophilia to autoimmune diseases. The process begins with fractionation, where plasma is separated into components like albumin, immunoglobulins, and clotting factors. These components are then purified and formulated into injectable or intravenous products.

For instance, CSL Behring’s Berinert—a plasma-derived therapy—is used to treat acute hereditary angioedema attacks. The protein C1 esterase inhibitor in Berinert is sourced from plasma donations, including those at CSL Plasma 161. Similarly, Gamunex-C, an immunoglobulin therapy, helps patients with primary immunodeficiency disorders by replenishing missing antibodies. Without facilities like CSL Plasma 161, the production of these therapies would be severely limited.

The demand for plasma-derived medicines is rising, driven by an aging population and increased prevalence of chronic diseases. CSL’s global network of plasma collection centers, including 161, ensures a stable supply chain. In 2023, the company processed over 1.5 million plasma donations worldwide, highlighting the scale of operations.

5. Career Opportunities at CSL Plasma 161

Beyond donation, CSL Plasma 161 offers career paths for those interested in healthcare, logistics, or biopharmaceuticals. Roles range from phlebotomists and donor relations specialists to quality assurance technicians and facility managers. Entry-level positions often require minimal experience, with on-the-job training provided.

For example, a phlebotomist at CSL Plasma 161 earns an average of $18–$22 per hour and is responsible for conducting plasma collections, monitoring donor comfort, and ensuring procedural compliance. Career growth is possible through certifications like Phlebotomy Technician (CPT) or Medical Laboratory Scientist (MLS). CSL also partners with local colleges to offer tuition reimbursement for employees pursuing relevant degrees.

The facility’s expansion in recent years has created demand for operations coordinators and supply chain specialists, who manage inventory, equipment maintenance, and donor scheduling. These roles are critical to maintaining the efficiency of CSL Plasma 161 and its contribution to therapeutic production.

6. Comparing CSL Plasma 161 to Other Plasma Centers

CSL Plasma 161 stands out among plasma collection centers due to its integration with CSL Behring’s manufacturing arm, ensuring a seamless transition from donation to therapy production. Unlike standalone centers that may sell plasma to third-party manufacturers, CSL’s vertically integrated model guarantees traceability and quality control. This alignment is particularly advantageous for patients who rely on CSL-derived therapies.

For donors, CSL’s compensation and donor experience often surpass competitors. While some centers offer higher per-donation payments, CSL’s frequent donor programs and health benefits—such as free HIV/hepatitis testing—add long-term value. Additionally, CSL’s centers are known for their clean, modern facilities and shorter wait times compared to some regional plasma providers.

However, factors like location and local demand can influence donor choice. For example, BioLife Plasma Services may have more centers in certain states, while Grifols focuses on Europe and Latin America. CSL’s U.S. presence, including CSL Plasma 161, remains a leader in plasma collection volume and therapeutic output.

7. The Future of Plasma Collection and CSL’s Role

Advancements in plasmapheresis technology and artificial intelligence-driven quality control are shaping the future of plasma collection. CSL Plasma 161 is at the forefront of these innovations, investing in automated plasma processing systems that reduce human error and increase yield. For example, single-donation plasma pools are being optimized to produce higher concentrations of therapeutic proteins, reducing the need for multiple donations per treatment.

Additionally, gene therapy and synthetic biologics may eventually reduce reliance on plasma-derived treatments. However, for now, plasma remains irreplaceable for conditions like hemophilia and primary immunodeficiencies. CSL’s research into next-generation plasma products, such as hyperimmune globulins for COVID-19, demonstrates its adaptive strategy. The company’s goal is to maintain a 10% annual growth rate in plasma collection by expanding facilities like CSL Plasma 161 and enhancing donor recruitment.

Sustainability is also a growing focus. CSL is exploring closed-loop plasma processing, where byproducts like red blood cells are repurposed for other medical uses, minimizing waste. These efforts align with the facility’s commitment to environmental stewardship while meeting the escalating global demand for plasma therapies.

Frequently Asked Questions

Curious about donating plasma or the role of CSL Plasma 161? Here are answers to common questions:

Question 1: How often can I donate plasma at CSL Plasma 161?

Donors can contribute plasma every 28 days, with a maximum of twice per week if medically cleared. CSL’s centers prioritize donor safety, ensuring adequate recovery time between sessions. Frequent donors may qualify for exclusive rewards programs, including higher compensation tiers.

Question 2: Is donating plasma safe during the COVID-19 pandemic?

Yes, CSL Plasma 161 follows CDC and FDA pandemic protocols, including mandatory mask-wearing, social distancing, and enhanced sanitization. Donors are screened for COVID-19 symptoms, and facilities maintain low occupancy to reduce transmission risks. Plasma collection resumed safely in 2020 with no reported outbreaks linked to donations.

Question 3: Can I donate plasma if I’ve had a tattoo or piercing?

CSL enforces a 12-month deferral period for tattoos or piercings obtained in state-regulated facilities. Piercings on hands, feet, or mucous membranes require a lifetime deferral. All tattoos must be fully healed before donation. Exceptions are granted only for medical or cultural piercings with documented professional oversight.

Question 4: What happens to my plasma after donation?

Plasma is transported to CSL’s Plasma Protein Therapeutics (PPT) division, where it undergoes fractionation and purification. Components like immunoglobulins and albumin are formulated into therapies for conditions such as multiple sclerosis or hemophilia. CSL provides transparency on how donations contribute to specific treatments through its annual reports.

Question 5: Are there age restrictions for plasma donation?

Donors must be at least 18 years old in most states, with an upper age limit of 65–75 depending on health status. CSL evaluates each donor individually, considering factors like blood pressure, hemoglobin levels, and overall vitality. Senior donors often have priority scheduling to accommodate their routines.

Question 6: How does CSL Plasma 161 ensure plasma quality?

Quality is maintained through multi-step testing, including serological and NAT (nucleic acid amplification) screens for infectious diseases. Plasma is also tested for protein content and purity before processing. CSL’s GMP-certified facilities adhere to strict temperature and handling protocols to preserve integrity from collection to therapy production.

10 Expert Tips for Donating Plasma at CSL Plasma 161

Maximize your plasma donation experience with these actionable tips:

Tip 1: Stay Hydrated Before Donation. Drink 16–24 ounces of water in the 24 hours leading up to your appointment to maintain blood volume and prevent dizziness. Avoid alcohol or caffeine, which can dehydrate you.

Tip 2: Eat a Balanced Meal with Iron-Rich Foods. Consume foods like lean meats, spinach, or lentils before donating to support hemoglobin levels. Low iron can lead to deferral, delaying your next donation.

Tip 3: Wear Comfortable Clothing with Easy Access to Veins. Opt for short sleeves and avoid tight sleeves that restrict blood flow. Phlebotomists prefer veins in the inner elbow or wrist, so expose these areas for a smoother process.

Tip 4: Schedule Donations During Off-Peak Hours. Arrive at CSL Plasma 161 during early mornings or late afternoons to avoid long wait times. Weekdays are typically less crowded than weekends.

Tip 5: Bring Valid ID and Proof of Residency. Required documents include a driver’s license, passport, or state-issued ID, plus proof of address (e.g., utility bill). Failure to provide these may result in a deferred donation.

Tip 6: Monitor Your Health Between Donations. Pay attention to signs of fatigue, bruising, or dizziness, which may indicate overdonation. CSL recommends waiting 48 hours between donations if you feel unwell.

Tip 7: Ask About First-Time Donor Bonuses. Some CSL Plasma 161 locations offer $10–$25 incentives for new donors. Check with the center or visit their website to confirm current promotions.

Tip 8: Use the CSL Mobile App for Appointments. The CSL Plasma app allows you to schedule, track donations, and access health records. Features like automatic reminders help maintain a consistent donation schedule.

Tip 9: Inquire About Plasma Protein Research Studies. CSL occasionally enrolls donors in clinical trials for emerging therapies. These studies may offer higher compensation and early access to innovative treatments.

Tip 10: Advocate for Plasma Donation in Your Community. Share your experience with friends or local groups to increase awareness. CSL’s Donor Advocacy Program provides materials to educate others about the life-saving impact of plasma donations.

Conclusion

CSL Plasma 161 exemplifies the intersection of medical innovation and community contribution, serving as a critical link between donors and life-changing therapies. From the meticulous screening process to the production of plasma-derived medicines, every step reflects CSL’s commitment to safety, efficiency, and patient impact. Donors benefit from financial compensation, health monitoring, and the satisfaction of supporting cutting-edge treatments, while patients gain access to therapies that improve or save lives.

As demand for plasma continues to rise, facilities like CSL Plasma 161 will play an even greater role in shaping the future of biopharmaceuticals. Whether you’re a prospective donor, a patient, or simply interested in the science behind plasma collection, understanding this process highlights the tangible ways individuals contribute to global health. The next step could be scheduling a donation—or exploring a career in this vital field.

• csl limited plasma operations
• csl plasma 161
• csl plasma collection process
• immunoglobulin production
• plasma derived therapies
• plasma donation benefits
• plasma protein therapeutics